文献速递神经技术与安全CT

碘对比剂相关脑病的多面表现:系统综述

The Many Faces of Contrast-Associated Encephalopathy: A Systematic Review.
PubMed 文献 · Br J Radiol · 2026-09-23

本研究对碘对比剂给药后出现的神经系统不良反应进行系统综述,纳入228篇文献,涉及对比剂脑病、对比剂神经毒性及短暂性皮质盲。多数表现可逆,常见于侵入性增强操作后。作者建议将不同术语统一为对比剂相关脑病。

要点

  • 碘对比剂相关神经症状多为卒中样表现或短暂性皮质盲,起病可在给药后24小时内。
  • 多数患者神经症状可逆,阅片遇到增强后新发神经功能缺损时需考虑对比剂相关脑病。
  • 慢性或终末期肾病、血管功能异常、对比剂用量及给药区域是主要风险因素。

核心结论

  • 现有证据提示碘对比剂相关神经系统不良反应存在共同病理生理基础,最可能与血脑屏障功能障碍有关。
  • 作者建议将对比剂脑病、对比剂神经毒性、短暂性皮质盲等不同术语统一归纳为「对比剂相关脑病」。
  • 多数患者的神经症状可逆,症状出现时间从对比剂给药后即刻至24小时不等。

研究设计与样本

  • 采用PRISMA-2020系统文献检索,纳入涉及碘对比剂给药后对比剂脑病、对比剂神经毒性及短暂性皮质盲的科学文献,共纳入228篇记录。

关键影像表现/征象

  • 患者常表现为卒中模拟征及短暂性皮质盲。

诊断标准与关键数值

  • 神经系统不良反应多数发生于侵入性对比增强操作后,文献中多描述为对比剂脑病、对比剂神经毒性及短暂性皮质盲。
  • 症状出现时间从碘对比剂给药后即刻至给药后24小时不等。

临床应用与阅片要点

  • 对增强检查后出现急性神经功能缺损者,鉴别诊断需纳入碘对比剂相关脑病,尤其是存在肾病或血管基础疾病者。
  • 报告相关病例时建议采用「对比剂相关脑病」统一术语,以提高临床对该不良反应的认知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The increased use of endovascular procedures shows an increase of neurological deficits after intravascular administration of iodine-based contrast media (ICM). Unfortunately, nonuniform terminology is confusing and may explain low awareness of this ICM-associated neurological adverse drug reaction (nADR). Consequently, we conducted this study to summarize identified risk factors, clinical presentations, radiological features, pathophysiological mechanisms, and treatment strategies of ICM-associated nADR. Additionally, we evaluated, if unifying different terminology of nADR seems to be warranted.

METHODS: A PRISMA-2020 systematic literature search was conducted. We included scientific articles on contrast-induced encephalopathy (CIE), contrast-induced neurotoxicity (CIN), and transient cortical blindness (TCB) following administration of iodine-based contrast media (ICM). A total of 228 records were eligible for inclusion.

RESULTS: The majority of neurological adverse reactions manifests after invasive contrast enhanced procedures and are mostly described as CIE, CIN, and TCB. Patients present with stroke mimickers and TCB. The onset of symptoms varies from shortly after the administration of ICM till up to 24 hours following ICM application. In most of the patients the neurological symptoms are reversible. The available evidence suggests that there seems to be a common underlying pathophysiology, most likely due to dysfunction of the blood brain barrier (BBB). Risk factors include chronic or end stage renal disease, underlying vascular dysfunction, ICM-volume, and the territory of ICM-administration.

CONCLUSIONS: There is need for implementation of formal criteria and raising awareness on risk factors and therapeutic management of nADR following ICM-administration. The authors suggest to summarize currently different terminology under one umbrella of contrast-associated encephalopathy (CAE).

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Heinz, Ökrösi, Wambacher, et al. The Many Faces of Contrast-Associated Encephalopathy: A Systematic Review. Br J Radiol. 2026. PMID: 42776609. doi:10.1093/bjr/tqag228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。